288-35-7

Usage

Uses

Used in Pharmaceutical Industry:
2H-1,2,3-Triazole is used as a key component in the development of pharmaceuticals due to its potential biological activities and its ability to be incorporated into various drug molecules, enhancing their therapeutic properties and effectiveness.
Used in Agrochemical Industry:
In the agrochemical sector, 2H-1,2,3-Triazole is utilized as a vital constituent in the synthesis of agrochemicals, contributing to the creation of more effective and targeted pesticides and other agricultural products.
Used in Materials Science:
2H-1,2,3-Triazole is employed as a crucial element in the production of advanced materials, where its unique chemical properties can be leveraged to develop new materials with specific characteristics for various applications.
Used in Natural Products Research:
2H-1,2,3-Triazole is found in some natural products and is used as a target for drug discovery and development, given its potential biological activities and the possibility of discovering new therapeutic agents from natural sources.

InChI:InChI=1/C2H3N3/c1-2-4-5-3-1/h1-2H,(H,3,4,5)

Upstream product

• 288-36-8 1,2,3-triazole 
• 61177-95-5 3-amino-1,2,4-triazine 2-oxide 
• 64-02-8 disodium ethylenediamine tetraacetic acid 
• 536-74-3 phenylacetylene 

Downstream Products

• 10261-02-6 2-(2-nitro-phenyl)-2H-[1,2,3]triazole 
• 10560-92-6 1-(2-nitrophenyl)-1H-1,2,3-triazole 
• 1628-89-3 2-methoxypyridine 
• 153653-01-1 2-(1,2,3-triazol-2-yl)pyridine 
• 584-14-5 1-amino-1,2,3-triazole 
• 13518-80-4 2-trimethylsilyl-2H-1,2,3-triazole 
• 63778-00-7 2-phenethyl-2H-[1,2,3]triazole 
• 63777-90-2 2-phenylethyl-1H-1,2,3-triazole 
• 85862-90-4 1-(4-(1H-1,2,3-triazol-1-yl)phenyl)ethan-1-one 
• 420-04-2 CYANAMID 
• 24153-51-3 diazomethane 
• 151-51-9 carbodiimide 
• 18922-72-0 2-(4-nitrophenyl)-2H-1,2,3-triazole 
• 1001401-62-2 2-(2H-1,2,3-triazol-2-yl)benzoic acid 

Relevant academic research and scientific papers

Process for the manufacture of functional PFPE derivative

A process for the manufacture of a functional (per)fluoropolyether derivative comprising at least one triazole group, such process comprising: (1) reacting a (per)fluoropolyether hydroxyl derivative having at least one hydroxyl group [derivative (PFPE-OH)] with an activating agent, to yield an activated (per)fluoropolyether hydroxyl derivative comprising at least one activated hydroxyl group [derivative (a-PFPE-OH)]; (2) reacting said activated (per)fluoropolyether hydroxyl derivative [derivative (a-PFPE-OH)] with at least one azide salt to yield a functional (per)fluoropolyether derivative comprising at least one azido group [derivative (PFPE-N3)]; and (3) reacting said functional (per)fluoropolyether derivative comprising at least one azido group [derivative (PFPE-N3)] with a hydrocarbon compound having a terminal alkyne group to yield a functional (per)fluoropolyether derivative comprising at least one triazole group [derivative (PFPE-azole)].

Substituted amino methyl factor Xa inhibitors

The present application describes substituted-aminomethyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Heteroaryl-phenyl substituted factor Xa inhibitors

The present application describes heteroaryl-phenyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of factor Xa.

Heteroaryl- phenyl heterobicyclic factor Xa inhibitors

The present application describes heteroaryl-phenyl heterobicycles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa

The present application describes inhibitors of factor Xa of formula I: or pharmaceutically acceptable salt forms thereof, wherein W, W1, W2, and W3may be N or C and J, Ja, and Jbcombine to form a substituted carbocycle or heterocycle.

6-membered aromatics as factor Xa inhibitors

The present application describes 6-membered aromatics of formula I: or pharmaceutically acceptable salt forms thereof, wherein D may be CH2NH2 or C(=NH)NH2, which are useful as inhibitors of factor Xa.

α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors

The present application describes m-amidino phenyl analogs of formula I: wherein D can be amidino and E can be phenyl, which are useful as inhibitors of factor Xa.

N-(AMIDINOPHENYL) CYCLOUREA ANALOGS AS FACTOR XA INHIBITORS

The present application describes N-(amidinophenyl)cyclourea analogs of formula I: STR1 which are useful as inhibitors of factor Xa.

INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP

The present application describes inhibitors of factor Xa with a neutral P1 specificity group of formula I: STR1 or pharmaceutically acceptable salt forms thereof, wherein R and E may be groups such as methoxy and halo.

SYNTHESIS OF THE FIRST MONOSUBSTITUTED 1,2,4-TRIAZINE DI-N-OXIDE. 13C NMR OF 1,2,4-TRIAZINE N-OXIDES AND USE OF HYDROGEN/DEUTERIUM ISOTOPE SHIFTS FOR THE ASSIGNMENTS OF SOME DIHYDRO-1,2,4-TRIAZINE TAUTOMERS

3-Amino-1,2,4-triazine 2,4-dioxide (4) was prepared by oxidation of 3-amino-1,2,4-triazine 2-oxide (3) with hydrogen peroxide in polyphosphoric acid, the first 1,2,4-triazine 2,4-dioxide ever reported.Some starting material gave ring contracted products as well as ring C-oxidation under a variety of reaction conditions employed in the attempted synthesis of the title compound (4). 13C nmr proved to be a method of choice for structural assignments of isomeric N-oxide.H/D isotope shifts unequivocally established the structures of compounds which could conceivably exist as several tautomers.